Glaxosmithkline Share News (GSK)

UK Dividends Calendar - Week Ahead

UPDATE: RBS Into Profit But Sets Aside GBP400 Million For Forex Probe

UK Dividends Calendar - Week Ahead

UK Dividends Calendar - Week Ahead

Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya

LONDON, Oct 29 (Reuters) - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a programme with funding from the Wellcome Trust. A $5 million grant from the medical

FTSE 100 movers: StanChart slides after third-quarter results disappoint

Shares in banking group Standard Chartered dropped after the company reported a 16% decline in operating profit in the third quarter and said that full-year earnings would be lower than last year. Shares in banking counterpart Standard Chartered dropped after the company reported a 16% decline in op

Swiss test GSK Ebola vaccine in some volunteers going to Africa

GENEVA, Oct 28 (Reuters) - Switzerland's drug regulator said on Tuesday it had approved the testing of an experimental Ebola vaccine from GlaxoSmithKline on healthy volunteers, some of whom will be travelling to West Africa as medical staff. The trial will be conducted among 120 volunteer p

GSK Nigeria 9-month pre-tax profit falls 25.9 pct

LAGOS, Oct 28 (Reuters) - The Nigerian unit of drugmaker GlaxoSmithKline on Tuesday said its 9-month pretax profit fell 25.9 percent to 2.06 billion Nigerian naira($12.47 million), compared with 2.78 billion naira the previous year. Turnover however rose to 23.21 billion naira during the n

Tuesday broker round-up UPDATE

Afren: Credit Suisse lowers target price from 132p to 115p staying with its outperform rating. African Barrick Gold: Westhouse moves target price from 230p to 240p and keeps an add rating. Anglo American: Investec reduces target price from 1603p to 1588p and keeps a buy recommendation. APR Energy:

UPDATE 2-Novartis results top forecasts as new products gain momentum

* Q3 sales $14.7 bln vs $14.54 bln f'cast * Core EPS $1.37 vs $1.31 poll f'cast * Growth products rise 21 pct * Says portfolio revamp on track * Shares up 2.2 percent (Adds details, CEO quote, shares) By Caroline Copley ZURICH, Oct 28 (Reuters) - Swiss drugma

DIRECTOR DEALINGS: Glaxo Chairman Exercises Options, Sells Shares

GSK shareholder-friendly policy shift could hurt credit profile, Fitch says

Fitch Ratings has warned that GlaxoSmithKline's (GSK) proposal to float part of its HIV drugs unit could hurt the group's credit profile. The proposed move, which is seen as the first step of a potential shift towards more "shareholder-friendly financial policies" coupled with the drugmaker's weak s

Broker tips: Lloyds, GlaxoSmithKline, Airlines

Lloyds may have passed the Europe-wide stress tests, but the UK's own bank-health checks may be an issue, according to broker Jefferies which downgraded the stock from 'hold' to 'underperform' on Monday. The broker reckons that Lloyds is now "at risk" ahead of the Prudential Regulation Authority's f

GlaxoSmithKline dividend 'still unsustainable', says UBS

UBS has cut its target price for GlaxoSmithKline after trimming its estimates for the pharmaceutical company, and said that its dividend "still looks unsustainable". The bank has reduced its target for the shares from 1,380p to 1,250p and kept a 'sell' rating. Following Glaxo's recent third-quarter

UPDATE 1-Australia's CSL buys Novartis flu vaccine unit for $275 mln

(Adds details from Novartis, changes dateline) SYDNEY/ZURICH, Oct 27 (Reuters) - Australia's CSL Ltd , the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's global influenza vaccine business for $275 million, part of the Swiss drugmaker's drive to foc